# Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

> **NCT00427999** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 67 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** imatinib mesylate
- **DRUG:** Treosulfane
- **DRUG:** etoricoxib
- **DRUG:** pioglitazone
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00427999
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2015-06
- **Final completion:** 2015-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427999, "Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00427999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*